...
{{^usCountry}}
{{/usCountry}}
Novavax to explore combined influenza/Covid-19 vaccine for use post pandemic
Reuters | Reuters| Posted by Susmita Pakrasi
Oct 13, 2020 07:04 PM IST
The flu vaccine, NanoFlu, met the primary and secondary goals in late-stage comparison study with Sanofi’s influenza vaccine Fluzone Quadrivalent earlier in the year.
Novavax Inc said on Tuesday it has set up a team of company veterans as it seeks U.S. regulatory approval for its seasonal influenza vaccine and to help develop a combined influenza/Covid-19 vaccine for use after the pandemic.
{{^usCountry}}
{{/usCountry}}
{{#usCountry}}
{{/usCountry}}
{{/userSubscribed}}
{{^usCountry}}
{{/usCountry}}
{{#usCountry}}
{{/usCountry}}
{{/userSubscribed}}
The flu vaccine, NanoFlu, met the primary and secondary goals in late-stage comparison study with Sanofi’s influenza vaccine Fluzone Quadrivalent earlier in the year.
{{^usCountry}}
{{/usCountry}}
{{^usCountry}}
{{/usCountry}}
Novavax is among global drugmakers racing to develop a vaccine for Covid-19 and last month started a late-stage trial of its experimental vaccine, NVX-CoV2373, in the United Kingdom.
NVX-CoV2373 is also being tested in two ongoing mid-stage trials that began in August.
